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Abstract: Cryopyrin-associated periodic syndromes (CAPS) are a group of inherited inﬂ ammatory 
disorders consisting of familial cold-induced autoinﬂ ammatory syndrome (FCAS), Muckle-Wells 
syndrome (MWS), and neonatal-onset multisystem inﬂ ammatory disease (NOMID; also known 
as chronic infantile neurologic, cutaneous, articular [CINCA] syndrome). These rare disorders are 
associated with heterozygous mutations in the NLRP3 (CIAS1) gene, which encodes the protein 
NALP3 or cryopyrin, and inﬂ ammation driven by excessive production of the cytokine interleukin-
1β (IL-1β). Amyloidosis is a serious complication with 25% of MWS patients developing amyloi-
dosis, with occasional fatal consequences, whilst up to 20% of CINCA/NOMID patients die from 
various complications, before reaching the early adulthood. In some CINCA/NOMID adult survivors 
amyloidosis can also occur. Prior to the discovery of the CIAS1 gene mutations and the advent of 
IL-1 targeted therapy, treatment was aimed at suppressing inﬂ ammation, with limited success. The 
selective blockade of IL-1β, with anakinra (IL-1 receptor antagonist), not only provided supportive 
evidence for the role of IL-1β in CAPS, but also demonstrated the efﬁ cacy of targeting IL-1β for 
treatment of these conditions. In February, 2008, ‘Orphan Drug’ approval from the Food and Drug 
Administration (FDA) for rilonacept (IL-1 Trap/Arcalyst™, Regeneron Pharmaceuticals, Inc) was 
given for the treatment of two CAPS disorders, FCAS and MWS in adults and children 12 years 
and older, making rilonacept the ﬁ rst therapy approved for the treatment of CAPS.
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Introduction
Cryopyrin-associated periodic syndrome (CAPS) is a group of inherited inﬂ ammatory 
disorders consisting of familial cold-induced autoinﬂ ammatory syndrome (FCAS; 
also known as familial cold urticaria [FCU]), Muckle-Wells syndrome (MWS), and 
neonatal-onset multisystem inﬂ ammatory disease (NOMID; also known as chronic 
infantile neurologic, cutaneous, articular [CINCA] syndrome). These disorders are 
associated with heterozygous mutations in the NLRP3 (CIAS1) gene, which encodes 
the protein NALP3 or cryopyrin, and inﬂ ammation driven by an excessive production 
of the inﬂ ammatory cytokine interleukin-1β (IL-1β). CAPS disorders are rare, and until 
recently there was no adequate therapy for their treatment. The elucidation of the path-
way involved in IL-1 signalling and its dysregulation underlying CAPS has enabled the 
development of IL-1-targeted therapies, such as the IL-1 receptor antagonist, anakinra. 
The aim of this review is to examine the long-term management of CAPS, focusing on 
rilonacept (IL-1 Trap/Arcalyst™; Regeneron Pharmaceuticals, Inc), the recent FDA 
approved treatment for MWS and FCAS in adults and children 12 years and older.
Clinical and pathological features of CAPS
The CAPS family of related conditions share a common genetic ancestry, but manifest 
as separate disease entities with overlapping clinical features, of variable severity. 
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Historically these conditions were identiﬁ ed and described 
independently of one another, with their diagnosis being 
based solely on their clinical features, prior to discovery of 
their common genetic origin.
FCAS was ﬁ rst described in 1940 as a rare disorder 
inherited in an autosomal dominant manner and characterized 
by intermittent attacks of rash, fever and arthralgias (Kile and 
Rusk 1940). MWS was named after two physicians, who, in 
1962, ﬁ rst described a British family with childhood onset of 
recurrent episodes of urticarial-like skin rash, fever, chills, 
malaise and piercing limb pains, with later development of 
sensorineural hearing loss and amyloidosis (Muckle and 
Wells 1962).
The ﬁ rst case of what was later to be known as CINCA 
in Europe and NOMID in North America, was described by 
Lorber in 1973 (Lorber 1973). He presented an 11-year-
old boy with dwarfism; persistently open fontanelle, 
recurrent subdural effusions, with temporary alternate-
sided hemiplegia, high-tone deafness, visual defects with 
pseudopapilloedema, slowing of intellectual development, 
recurrent acute polyarthritis, erythema marginatum, 
splenomegaly and iron-resistant hypochromic anemia. 
Subsequently, a case series of 30 patients from France was 
used to clinically deﬁ ne the CINCA/NOMID syndrome 
(Prieur et al 1987).
FCAS, MWS and CINCA/NOMID share a number of 
features but also have some distinctive clinical manifesta-
tions, which together deﬁ ne the disease continuum that is 
CAPS, with FCAS at the mild end of the disease spectrum, 
CINCA/NOMID at the severe end and MWS somewhere 
in the middle.
All three forms usually present in infancy and early 
childhood, and symptoms may be present at birth in the case 
of CINCA/NOMID. In keeping with the varying severity of 
these conditions, the length of attacks also varies accordingly. 
In the case of FCAS and MWS, where the onset of an attack 
is usually marked by fevers and chills, the symptoms last 
up to 24 hours in FCAS, and up to several days, or rarely 
continuously in MWS. In CINCA/NOMID the periodic-
ity of the attacks is lost and, instead, there is a low-level 
continuous disease activity, with an occasional disease 
ﬂ are-up (Table 1).
Urticarial-like skin rash is universally present in all 
CAPS patients. Although it was claimed that exposure to 
cold typically precipitates attacks of just FCAS, similar 
observations have also been made for MWS patients (Haas 
et al 2004). Unlike acquired cold-induced urticaria, where the 
skin lesions are localized and induced almost immediately 
following, for example, ice cube provocation testing, in 
FCAS and MWS, the onset of symptoms is usually delayed 
for hours following generalized exposure to cold tempera-
tures and the ice cube provocation test is negative (Haas et al 
2004; Hoffman et al 2001). Urticaria may be persistent in 
CINCA/NOMID patients.
There is also a predictable gradation of severity of 
articular symptoms, which are universal in all CAPS 
patients, from arthralgia in FCAS, polyarticular arthritis 
in MWS to severe joint deformities typical of CINCA/
NOMID. The latter has highly characteristic features, 
such as distinctive radiographic changes of premature 
patellar and epiphyseal long bone ossiﬁ cation, leading to 
osseous overgrowth in early life and subsequent severe 
Table 1 Cryopyrin-associated periodic syndromes (CAPS) features
CAPS FCAS MWS CINCA/NOMID
Genetics Inheritance Autosomal dominant Autosomal dominant Majority are de novo
C
lin
ic
al
 fe
at
ur
es
Locus, gene, protein 1q44, CIAS1, cryopyrin 1q44,CIAS1, cryopyrin 1q44,CIAS1, cryopyrin
Onset Childhood Childhood From birth
Duration of attacks Up to 1 day Several days or continuous Continuous
Cutaneous Urticarial rash Urticarial rash Urticarial rash, neutrophilic eccrine hidradenitis
Musculoskeletal Arthralgia Arthritis Epiphyseal overgrowth and joint deformity
Neurological Conjuctivits, 
headaches
Conjunctivitis, deafness Meningitis, mental retardation, deafness
Morphological None None Short statute, frontal bossing, delayed closure
of fontanelles, saddle nose, clubbing
Amyloid No Yes Yes
Abbreviations: CINCA, chronic infantile neurologic cutaneous articular syndrome; FCAS, familial cold-induced autoinfl ammatory syndrome; MWS, muckle wells syndrome; 
NOMID, neonatal-onset multisystem infl ammatory disease.
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contractures and disability (Kaufman and Lovell 1986; 
Torbiak et al 1989).
As a part of the triad that involves dermatological, 
arthropathic and neurological symptoms, which are typical of 
CAPS, neurological manifestations of the disease are, again, 
most severe in CINCA/NOMID and almost non-existent in 
FCAS. Neurological problems that have been encountered in 
CINCA/NOMID patients include chronic septic meningitis, 
cerebral atrophy and mental retardation, cerebral ventricular 
dilatation, pseudopapilloedema and high-frequency hearing 
loss (Hashkes and Lovell 1997). The latter is also the prin-
cipal neurological complication found in MWS, but not in 
FCAS. All three disease entities have frequent ocular involve-
ment, which include conjunctivitis in FCAS, conjunctivitis 
and episcleritis in MWS (Farasat et al 2008) and uveitis in 
CINCA/NOMID (Dollfus et al 2000).
There are a number of morphological features that are 
typical of CINCA/NOMID alone, and include short stature, 
enlarged head, saddleback nose and short and thick extremities, 
with clubbing of ﬁ ngers. No morphological changes have been 
observed in FCAS and MWS (Neven et al 2008).
Prior to the availability of current treatments, which mainly 
consist of various anti-interleukin-1 (IL-1) therapeutics, only 
FCAS had a benign prognosis. Around 25% of MWS patients 
developed amyloidosis (Dode et al 2003), with occasional 
fatal consequences, whilst up to 20% of CINCA/NOMID 
patients died from various complications, such as infec-
tion, vasculitis and amyloidosis, before reaching adulthood 
(Hashkes and Lovell 1997). Amyloidosis is also seen in a 
proportion of surviving CINCA/NOMID patients.
Most of the signs and symptoms that clinically deﬁ ne CAPS 
are the result of an inappropriate inﬂ ammatory response. Earlier 
studies have consistently shown elevated white cell counts in 
the peripheral blood, with predominant polymorphonuclear 
leukocytosis and raised CRP and ESR during the attacks. Fur-
thermore, skin biopsies of the affected areas have shown an 
inﬂ ammatory inﬁ ltrate consisting of neutrophils, eosinophils 
and lymphocytes, in the absence of mast cells and concentrated 
around vascular walls of dilated capillaries (Farasat, 
Aksentijevich, and Toro 2008; Haas, Kuster, Zuberbier, and 
Henz 2004). MRI investigations of the brain have demonstrated 
leptomeningial and cochlear enhancement, consistent with 
oedema and inﬂ ammation (Neven et al 2008).
Genetics
Prior to discovery of genetic mutations responsible for 
CAPS, the cause of the excessive inﬂ ammation was largely 
unknown. The investigations were limited to exclusion of 
known autoimmune diseases, by demonstrating the absence 
of the more common autoantibodies, such as anti-nuclear 
antibodies (ANA) and rheumatoid factor (RF).
Genetic studies using large families with FCAS and 
MWS led to identification of chromosome 1q44 as a 
susceptibility locus for these diseases (Cuisset et al 1999; 
Hoffman et al 2000). Subsequently, FCAS and MWS 
were shown to be associated with mutations in the NLRP3 
(Nucleotide binding oligomerization domain, Leucine 
rich Repeat and Pyrin domain containing 3)/CIAS1(Cold-
Induced Autoinﬂ ammatory Syndrome 1) gene, which codes 
for cryopyrin or NALP3 (Aganna et al 2002; Dode et al 
2002b; Hoffman et al 2001). Later still missense muta-
tions in CIAS1 were also found in a number of unrelated 
CINCA syndrome patients (Feldmann et al 2002). To date 
more then 70 CAPS associated, mainly missense muta-
tions found in exon 3 of CIAS1, have been registered with 
the INFEVERS database (http://fmf.igh.cnrs.fr/infevers). 
There is a variable genotype/phenotype correlation. Some 
of the mutations are exclusively associated with one of the 
syndromes, whilst others can produce alternative clinical 
manifestations. Mutations such as R260W, V198M, V262G 
can all, for example, result in MWS or FCAS (Dode et al 
2002a), whilst on the other hand, Y570, F309SA and F523L 
are exclusively associated with severe forms of CINCA 
(Aksentijevich et al 2002). Although CAPS are inherited in 
an autosomal dominant manner, with a gain of function of 
the mutated protein, this variability in the clinical manifesta-
tions suggests that other modiﬁ er genes and environmental 
factors probably play a signiﬁ cant part in the pathogenesis 
of these conditions.
In addition to patients who carry recognisable CIAS1 
mutations, there are a number of patients in whom such 
mutations are not present but have clinically apparent 
CAPS. The search for mutations in genes that are func-
tionally associated or related to CIAS1, for example ASC 
(Apoptosis-associated Speck-like protein containing a 
Caspase recruitment domain), in such patients has so far 
largely been unsuccessful. A recently discovered mutation 
in CASP1, leading to a structurally altered caspase-1 with 
decreased enzyme activity and a condition provisionally 
called ICE fever, might suggest an alternative pathway 
leading to the pro-inﬂ ammatory immunopathological proﬁ le 
similar to CAPS. Patients affected by this mutation all suffer 
from recurrent febrile episodes accompanied by arthralgia, 
exanthema and elevated systemic markers of inﬂ ammation. 
Although the accepted hypothesis of CAPS pathogenesis 
(discussed below) postulates the excess of active IL-1β as 
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the principal consequence of CIAS1 mutations leading to the 
manifestation of the clinical disease, the CASP1 mutation 
appears to exert its pro-inﬂ ammatory effect by engaging 
RIP2, resulting in excessive activation of NF-κB and MAPK 
pathways (Touitou et al 2008).
Another explanation why certain patients have a clinical 
disease but no obvious genetic mutation has been offered by 
a Japanese group (Saito 2005, 2008), which has described a 
CINCA patient with a somatic mosaicism. Careful sequenc-
ing and analysis of patient’s exon 3 of CIAS1 demonstrated 
point mutations, 587G  A (S196N) and 1709A  G 
(Y570C). Although the first point mutation was easily 
identiﬁ ed to be a relatively rare SNP, the second mutation, 
which is associated with a severe CINCA phenotype, was 
much harder to identify as the chromatograﬁ c intensity of 
the mutated G at the position 1709 was considerably lower 
than that of A at the same position. This was suggestive of 
somatic mosaicism, whereby only a proportion of somatic 
cells carried the mutation. Further analysis demonstrated 
that the mutation occurred with a frequency of 16.7 in whole 
blood and that it was present in several cell lines. The patient 
had all the clinical features consistent with CINCA and the 
analysis of their PBMC showed spontaneous and excessive 
IL-1 production.
Immunopathology
Identiﬁ cation of NALP3 as a target protein of CAPS associ-
ated mutations has led to a better understanding of immuno-
pathology of CAPS and development of targeted therapeutic 
interventions.
NALP3 belongs to a large family of proteins, which are 
collectively known as NLRs [NOD (nucleotide-binding and 
oligomerization domain) Like Receptors] due to their char-
acteristic tri-domain structure with C-terminal ligand-binding 
and regulatory LRR (Leucin-Rich Repeat) domain, a central 
nucleotide-binding and oligomerization NACHT domain and 
an N-terminal protein-protein interaction domain, which in 
case of NALP3 is PYD (Ting et al 2006). Like the majority of 
NLR proteins NALP3 is widely distributed in cells of innate 
immune cells including macrophages, neutrophils and den-
dritic cells as well as epithelial cells lining the oral and genital 
tracts (Kummer et al 2007). This reﬂ ects the principal func-
tion of this protein, which is to detect danger signals and as a 
part of multimeric protein complex, known as NALP3 inﬂ am-
masome, regulate IL-1ß and IL-18 production (Martinon et al 
2002). Monosodium urate (Martinon et al 2006), calcium 
pyrophosphate and silica crystals (Cassel et al 2008), alumin-
ium hydroxide (a vaccine adjuvant) (Eisenbarth et al 2008), 
DNA fragments (Muruve et al 2008), ATP and potassium 
ﬂ ux (Petrilli et al 2007) have all so far been identiﬁ ed as 
danger signals recognized by NALP3 in the context of infec-
tion and/or tissue damage. Following ligand binding, which 
is thought but not proven to be via LRR domain, NALP3 
undergoes NACHT domain-mediated self-oligomerization. 
This leads to activation of N-terminal domain and subse-
quent PYD-PYD homologous protein interaction leading to 
the recruitment of the ASC adaptor protein, which together 
with CARDINAL activates caspase-1, which, in turn cleaves 
pro-IL-1ß into its active form (Church et al 2008; Martinon 
et al 2002) (Figure 1).
The majority of mutations associated with CAPS are 
clustered within the highly conserved NACHT domain of 
NALP3. It has been proposed that these mutations have a gain 
of function effect, leading to spontaneous oligorimerization 
of NALP3 subunits around mutated NACHT domains and 
subsequent caspase-1 activation resulting in an excessive and 
inappropriate IL-1β release (Agostini et al 2004; McDermott 
and Aksentijevich 2002). This hypothesis is supported by 
observations that monocytes from patients with MWS and 
CINCA/NOMID spontaneously secrete IL-1β (Rosengren 
et al 2007). Furthermore, therapeutic inhibition of IL-1β 
action has been shown to be effective in reducing the disease 
activity and leading to symptomatic improvement in the 
majority of CAPS patients.
Standard treatment
Prior to the discovery of mutations of the CIAS1 gene 
mutation underlying CAPS and the advent of IL-1 targeted 
therapy, treatment for patients with CAPS was aimed at 
suppressing inﬂ ammation, and have included high-dose 
corticosteroids, disease-modifying anti-rheumatics drugs 
(DMARDS) and biologics targeting tumour necrosis factor 
(TNF), such as etanercept. CAPS patients have unfortunately 
been relatively refractory to most of these treatments.
IL-1-targeted therapy
The identiﬁ cation of the CIAS1 mutations and the elucidation 
of the molecular basis for MWS, FCAS and CINCA/NOMID 
identiﬁ ed these diseases as part of a disease spectrum associ-
ated with the excessive production of IL-1β. The selective 
blockade of IL-1β provided supportive evidence for the role of 
IL-1β in CAPS, while also demonstrating the effectiveness of 
targeting IL-1β for the successful treatment of these conditions 
(Goldbach-Mansky et al 2006; Hawkins et al 2003, 2004a, b; 
Hoffman et al 2004; Leslie et al 2006; Maksimovic et al 
2008; Mirault et al 2006; O’Connell et al 2007; Ross et al 2008; 
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Rynne et al 2006). Currently, there are a number of IL-1 
inhibitors at various stages of development. These include 
monoclonal antibodies to IL-1 and ‘cytokine traps’, such as 
anakinra (Kineret™), canakinumab (ACZ885), and rilonacept 
(Arcalyst™).
Anakinra
Anakinra is a recombinant nonglycosylated human IL-1 
receptor antagonist (rHuIL-1ra) that consists of 153 amino 
acids with a molecular weight of 17.3 kDa, and is identical 
(except for the addition of one N-terminal methionine) to the 
naturally occurring form of human IL-1 receptor antagonist 
(IL-1ra). The use of anakinra by daily subcutaneous injec-
tions has been approved for the treatment of rheumatoid 
arthritis (RA). Despite the modest efﬁ cacy of anakinra in 
RA (Clark et al 2004; Taylor 2003), several studies and 
case reports following the administration guidelines for RA 
have now been published, with impressive evidence of its 
remarkable efﬁ cacy in the treatment of MWS, FCAS and 
CINCA/NOMID (Goldbach-Mansky et al 2006; Hawkins 
et al 2003, 2004a, b; Hoffman et al 2004; Leslie et al 2006; 
Maksimovic et al 2008; Mirault et al 2006; O’Connell et al 
2007; Ross et al 2008; Rynne et al 2006). This striking 
improvement probably reﬂ ects the predominance of IL-
1β in mediating the symptoms associated with CAPS, 
compared with the complex and multiple inﬂ ammatory 
pathways which underlie the pathogenesis of RA. One of 
the largest studies, by Goldbach-Mansky and colleagues, 
recruiting 18 patients with CINCA/NOMID, demonstrated a 
rapid response to anakinra, with markedly improved clinical 
and laboratory measures. Rash and conjunctivitis subsided 
within three days in all cases, whilst diary scores of symp-
toms were decreased at three months. The ESR, and serum 
levels of amyloid A and CRP, fell signiﬁ cantly during treat-
ment in all patients (Goldbach-Mansky et al 2006). Interest-
ingly, reports have shown an improvement in hearing in 
those MWS and CINCA/NOMID patients who received 
anakinra (Goldbach-Mansky et al 2006; Mirault et al 2006; 
Rynne et al 2006), while others have found anakinra to stabi-
lize hearing loss (Maksimovic et al 2008). The study by Leslie 
and colleagues demonstrated that anakinra facilitated the 
resolution of AA amyloidosis-associated renal dysfunction. 
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Figure 1 Activation of the NALP3 infl ammasome. Engagement of specifi c TLRs (Toll-like receptors) leads to activation of NF-κB (nuclear factor κB) signaling pathways, inducing 
the expression of pro-IL-1β. NALP3 is the central component of the NALP3 infl ammasome; in its inactive state the LRR (leucine-rich repeat) domain of NALP3 is thought to 
self-associate, preventing interaction with CARDINAL or ASC (apoptosis-associated speck-like protein containing a CARD). NALP3 activation by agonists, such as ATP, uric 
acid crystals, bacterial messenger RNA, or aluminium hydroxide, unfolds the NALP3 molecule, enabling the assembly of the infl ammasome components CARDINAL, ASC, and 
pro-caspase-1 through homotypic interactions between their respective pyrin (PYD) and CARD (caspase recruitment domain) domains; CARDINAL interacts with the NAD 
domain of NALP3 through its FIIND (domain with function to fi nd) domain. The oligomerization of infl ammasome complexes induces cleavage of pro-caspase-1 to its active 
form, resulting in the generation of active IL-1β from its inactive precursor pro-IL-1β.
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In that study, serum AA and CRP normalized within 1 week 
in all patients, while serial SAP scintigraphy revealed regres-
sion of amyloid within 8 to 33 months in 3 patients who had 
AA amyloidosis (Leslie et al 2006). This observation is of 
particular signiﬁ cance considering that one quarter of patients 
with MWS will develop AA amyloidosis (Hawkins et al 
2004b). The AA amyloidosis usually manifests as impaired 
renal function, typically leading to renal failure and eventual 
death within 10 years in the absence of effective therapy. 
This harsh fact was particularly demonstrated in that study 
in which 3 of 6 patients in their series developed end-stage 
renal failure before the advent of anakinra, leading to the 
death of 2 of them (Leslie et al 2006).
Withdrawal of anakinra treatment led to a very rapid 
regression of symptoms within days. Symptoms were 
brought under control following re-initiation of anakinra, 
demonstrating the requirement of daily maintenance with 
this drug (Goldbach-Mansky et al 2006; Hawkins et al 2006; 
Maksimovic et al 2008).
ACZ885
ACZ885 (Canakinumab), a fully humanized monoclonal 
antibody against IL-1β, currently in phase III development, has 
demonstrated promising results during testing of the safety and 
pharmacokinetics for use of this therapy for treatment of CAPS 
(Kuemmerle-Deschner et al 2008; Lachmann et al 2006) and 
possibly other complex inﬂ ammatory diseases, such as RA (Alten 
et al 2008), systemic juvenile idiopathic arthritis (sJIA), psoriasis, 
and inﬂ ammatory bowel disease. Monoclonal antibody therapies 
are often advantageous over other forms of biologic therapies due 
to their relative longer half-lives, thus ensuring full neutralization 
of the target over a longer period of time. In April 2008, phase II 
data were reported at the Fifth International Congress on Familial 
Mediterranean Fevers and Systemic Autoinﬂ ammatory Diseases 
in Rome, Italy. ACZ885 demonstrated long-lasting clinical 
remission in patients with CAPS. The 50-patient study treated 
adult CAPS patients with a 150 mg injection of the drug every 
8 weeks and pediatric patients with 2 mg/kg. Patients’ symptoms 
displayed improvement within 1 day and all achieved complete 
clinical remission within 7 days. The drug was well tolerated 
and patients remained in remission for an average of 115 days. 
Phase III studies are still ongoing (Lachmann et al 2008), but 
ACZ885 has recently been granted EU and US Orphan drug 
status for treatment of CAPS.
Rilonacept (IL-1 Trap/Arcalyst™)
In February 2008, Regeneron pharmaceuticals received 
‘Orphan Drug’ approval from the Food and Drug Administration 
(FDA) for rilonacept (IL-1 Trap/Arcalyst™) for the treatment 
of two CAPS disorders, FCAS and MWS, in adults and chil-
dren aged 12 years and older. This made rilonacept the ﬁ rst 
therapy to be approved for the treatment of CAPS (Ratner 
2008). Rilonacept is a fusion protein, the product of ‘Trap’ 
technology, designed to bind to and neutralize IL-1 before it 
can bind to cell surface receptors and induce inﬂ ammation. 
It is a dimeric glycoprotein, consisting of the human IL-1 
receptor extracellular domains and the Fc portion of human 
IgG1, with a molecular weight of approximately 251 kDa. 
In a single molecule, rilonacept incorporates both receptor 
components required for signalling namely the IL-1 type 
1 receptor and the IL-1 receptor accessory protein (AcP). 
One clear advantage of the structure of this fusion protein is 
the ability to bind to both IL-1α and IL-1β with high afﬁ nity 
(Economides et al 2003). This has the potential to ensue that 
rilonacept better efﬁ ciency to inhibit IL-1 in vivo than other 
IL-1 targeted therapies. Further to this, rilonacept can be 
administered weekly by subcutaneous injection, as opposed 
to the daily administration required for anakinra.
The FDA based its approval upon phase III clinical studies 
supported by Regeneron Pharmaceuticals, Inc., which dem-
onstrated the drugs safety and effectiveness (Hoffman et al 
2008). Changes in disease activity were measured in 47 adult 
patients with CAPS (44 with FCAS and 3 with MWS), 
using a composite symptom score compiled from a daily 
questionnaire (Daily Health Assessment Form [DHAF]), 
evaluating signs of rash, feelings of fever/chills, joint pain, 
eye redness/pain, and fatigue, using a scale of zero (none/ 
no severity) to 10 (very severe) (Hoffman et al 2008). The 
study was conducted in a randomized, double-blind, placebo 
controlled manner in two parts (1 and 2) in the same patients 
with FCAS and MWS. In study 1, patients either received 
160 mg weekly dose of rilonacept, after an initial loading 
dose of 320 mg, or placebo for 6 weeks. In Study 2, which 
followed immediately after study 1, all subjects were given 
160 mg rilonacept weekly for 9 weeks in a patient-blind 
manner, followed by a 9 week randomized, double blind 
withdrawal period in which patients were randomly assigned 
to either remain on treatment at 160 mg per week or to 
receive placebo. In study 1, 24 patients received rilonacept, 
and a signiﬁ cant reduction in mean symptom score was 
demonstrated compared with the 23 patients that received 
the placebo for the same period. Furthermore, study 2, the 
mean symptom scores increased more in those patients 
withdrawn to placebo compared with patients who remained 
on rilonacept. Rilonacept was tolerated well by these patients. 
The most common adverse reactions reported were injection 
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site reactions and upper respiratory tract infections, similar 
to those reported for anakinra treatment.
The design of this phase III study was based upon the 
ﬁ ndings of an initial pilot study of 5 patients with FCAS. In 
that open-label trial, a signiﬁ cant improvement, with sustained 
response and good tolerability to rilonacept, was reported 
(Goldbach-Mansky et al 2008). Following a baseline evalua-
tion, all patients received an initial loading dose of 300 mg of 
rilonacept by subcutaneous injection. The patients were then 
evaluated 6 and 10 days later for clinical efﬁ cacy, and remained 
off drug until a clinical ﬂ are occurred. At that time the patients 
received 300 mg of rilonacept and were then maintained on 
100 mg weekly doses, as part of an extension study. Patients 
whose symptoms were not controlled (CRP  0.5 mg/dL 
and/or SAA  10 mg/L and a daily diary score of  0.5, not 
achieved) could have their dose increased to 160 mg per week 
and then further to 320 mg per week in an intra-patient dose 
escalation phase.
Compared to the phase III study, this pilot clinical trial 
assessed safety, disease activity (determined by 3 symptom 
[rash, joint pain/swelling, and fever] compiled score recorded 
in a daily diary), quality of health (SF-36 questionnaire) and 
also markers of inﬂ ammation (ESR, CRP, SAA and IL-6), at 
3, 6, 9, 12 and 24 months post initiation of rilonacept admin-
istration, and compared with baseline measurements.
Within hours of receiving the initial dose of rilonacept, 
all patients reported beneﬁ t with a decrease in cold-induced 
attacks and improvements in symptoms as measured by 
reduction in daily scores. Three patients with hearing loss 
demonstrated no further deterioration during the two years of 
observation. Maximal clinical improvement was observed in 
four patients at day 10, and one patient at day 6. The improve-
ment in daily scores was accompanied by decreases in ESR, 
CRP and SAA levels. All patients entered the extension 
phase, and completed 24 months of follow up at a dose of 
160 mg/week or higher. At the higher doses, a statistically 
signiﬁ cant improvement was seen in the reduction of the ESR 
(p  0.05), and a trend towards further improvement in CRP 
and SAA level reduction. Four of the ﬁ ve patients did not 
fulﬁ l the criteria for CRP and the daily scores at 160 mg/week 
dose and were subsequently increased to 320 mg/week. The 
magnitude of improvement was less pronounced in the dose 
increase from 160 mg/week to 320 mg than that observed 
for 100 mg up to 160 mg/week. IL-6 levels were elevated at 
baseline but were decreased to undetectable levels at a dose of 
160 mg/week in all patients. These observations established 
160 mg/week as the favored dose for the subsequent phase III 
study described above.
The results of both of these studies are consistent, with 
rilonacept inducing a rapid and sustained reduction in the 
signs and symptoms of CAPS, regardless of the method of 
assessment. In the phase III study, rilonacept almost abol-
ished the occurrence of ﬂ ares, which was paralleled with 
decreases in the limitations of work, social and other activi-
ties. Although some patients showed the development of 
anti-rilonacept antibodies, there was no evidence that these 
inhibited the efﬁ cacy or safety of the drug. Whether there may 
be any further clinical signiﬁ cance of these antibodies is not 
yet determined and requires future follow-up. The patients 
tolerated rilonacept favorably in both studies, with reported 
adverse reactions considered only as mild or moderate.
Preliminary data suggests a beneﬁ cial effect of rilonacept 
in other inﬂ ammatory conditions including Familial Mediter-
ranean Fever (FMF) (Hashkes et al 2008), sJIA (Lovell et al 
2006a, b) and gouty arthritis (Radin et al 2008; Terkeltaub 
et al 2007).
Conclusions
The identification of the mutations in the CIAS1 gene 
and subsequent elucidation of the molecular mechanisms 
underlying the symptoms of CAPS accompanied with the 
development of IL-1 targeting biologics has been a triumph 
for translational research and a major therapeutic advance 
for patients suffering with CAPS. Indeed the future for 
CAPS patients has never seemed brighter, with current 
availability of not one but several biologic agents which 
will undoubtedly transform the lives of affected patients. 
For the medical community, the availability of anakinra, 
rilonacept and ACZ885 in their treatment armamentarium, 
has transformed the prognosis and treatment of patients from 
one of limited success to one of muted conﬁ dence, with 
the toughest decision being the choice of which biologic 
to prescribe. Ignoring the potential costs of each treatment, 
the ability to personalize treatment to the speciﬁ c needs of 
individual patients is a powerful and welcome tool. The IL-1 
blockade ﬂ agship, anakinra, has been pivotal in the determi-
nation of the molecular mechanisms of CAPS and a pioneer 
in the successful and sustained treatment of CAPS. Yet the 
frequent and high dose injections are not always tolerated 
well by patients. The desirable longer half-lives of rilonacept 
and ACZ885 offer potential alternatives to patients who 
tolerate daily injections poorly or have difﬁ culty with drug 
compliance. The initial evidence for the beneﬁ cial effects of 
rilonacept for MWS and FCAS suggests that it might also be a 
suitable treatment for CINCA/NOMID, but as of yet no clini-
cal trials of rilonacept have been performed in patients with 
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this condition. It is yet to be determined whether rilonacept 
or ACZ885 will have any greater efﬁ cacy in treatment of 
other chronic inﬂ ammatory conditions, such as RA, where 
anakinra has up to now proven little beneﬁ t.
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